BEIGF:OTCMKTS
BeOne Medicines
21,95 $
0,00%
(0,00) 1 p
9. juuni, 12:49:46 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse BEIGF põhistatistika genereerimine…
Turu kapit.
43,04 mld
Keskm. maht
0,00
Maht
0,00
52 näd kõrgeim
24,92 $
52 näd madalaim
21,95 $
Beeta
0,84
Käibivad aktsiad
1,43 mld
Töötajate arv
12 tuh
Turu kapit.
43,04 mld
Keskm. maht
0,00
Maht
0,00
52 näd kõrgeim
24,92 $
52 näd madalaim
21,95 $
Beeta
0,84
Käibivad aktsiad
1,43 mld
Töötajate arv
12 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
AD HOC NEWS
·
1 päeva eest
RBC raises target for BeOne Medicines stock to USD 459.00
Profiil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Teave üksuse BeOne Medicines kohta
TegevjuhtJohn Vincent Oyler | John Vincent Oyler
Töötajad12 tuh
Asutatud28. okt 2010
Peakontorid-
Sektor-
Veebisaitbeonemedicines.com